LY2787106 is a humanized monoclonal antibody designed to neutralize bioactive human hepcidin-25. Hepcidin is the master hormonal regulator of systemic iron homeostasis, which limits iron release into the bloodstream by inducing the internalization and degradation of ferroportin, the only known cellular iron exporter. In states of chronic inflammation and cancer, abnormally elevated hepcidin causes iron sequestration. LY2787106 potently neutralizes circulating hepcidin, blocking its action on ferroportin and thereby mobilizing stored iron to increase serum iron levels and support erythropoiesis, specifically for managing cancer-associated anemia.